Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
Partner Content Partner Content Spotlight on Key Sessions You Cannot Miss at Ophthalmic Drug... Are you aware the ophthalmic market is expected to reach $21 billion by the year 2022?
News Neurogene falls again on Rett gene therapy side effects Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.
